1. DeSantis, C. E., Lin, C. C., Mariotto, A. B., Siegel, R. L., Stein, K. D., Kramer, J. L., Alteri, R., Robbins, A. S., & Jemal, A. (2014). Cancer treatment and survivorship statistics, 2014. CA: a Cancer Journal for Clinicians, 64, 252–271.
2. Jahanban-Esfahlan, R., et al. (2019). Tumor cell dormancy: threat or opportunity in the fight against cancer. Cancers (Basel), 11, 1207.
3. Yuhas, J. M., & Tarleton, A. E. (1978). Dormancy and spontaneous recurrence of human breast cancer in vitro. Cancer Research, 38, 3584–3589.
4. Romero, I., Garrido, F., & Garcia-Lora, A. M. (2014). Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. Cancer Research, 74, 6750–6757.
5. Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009). Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunology, Immunotherapy, 58, 49–59.